Full Text View
Tabular View
No Study Results Posted
Related Studies
Safety and Efficacy of an Artificial Tear for the Treatment of Dry Eye
This study has been completed.
Study NCT00514852   Information provided by Allergan
First Received: August 8, 2007   Last Updated: May 28, 2008   History of Changes

August 8, 2007
May 28, 2008
October 2007
January 2008   (final data collection date for primary outcome measure)
Dry eye symptoms as measured by OSDI© [ Time Frame: Day 30 ] [ Designated as safety issue: No ]
Dry Eye Symptoms
Complete list of historical versions of study NCT00514852 on ClinicalTrials.gov Archive Site
  • Schirmer Test [ Time Frame: Day 30 ] [ Designated as safety issue: No ]
  • Tear Break-Up Time [ Time Frame: Day 30 ] [ Designated as safety issue: No ]
  • Staining [ Time Frame: Day 30 ] [ Designated as safety issue: No ]
  • Patient Acceptability [ Time Frame: Day 30 ] [ Designated as safety issue: No ]
Dry eye signs and patient acceptability
 
Safety and Efficacy of an Artificial Tear for the Treatment of Dry Eye
 

The efficacy, safety and acceptability of a new artificial tear in subjects with dry eye will be compared to a currently-available artificial tear

 
 
Interventional
Treatment, Randomized, Double Blind (Subject, Investigator), Parallel Assignment, Safety/Efficacy Study
Dry Eye Syndrome
  • Drug: Carboxymethylcellulose and Glycerin based artificial tear
  • Drug: Carboxymethylcellulose
  • Experimental: Carboxymethylcellulose and Glycerin based artificial tear
  • Active Comparator: Carboxymethylcellulose
 

*   Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
 
Completed
316
January 2008
January 2008   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Mild, moderate or Severe Symptoms of Dry Eye

Exclusion Criteria:

  • Uncontrolled systemic disease
  • Use of systemic medications affecting dry eye
  • Pregnancy or planning a pregnancy
  • Contact lens wear
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00514852
Therapeutic Area Head, Allergan, Inc.
AG9818-002
Allergan
 
Study Director: Medical Director Allergan
Allergan
May 2008

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP